The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE

Table 2 Correlation between AST/ALT ratio and clinicopathological variables of patients with hepatocellular carcinoma

Variables	AST/ALT ≤ 0.89 (n = 32)	AST/ALT > 0.89 (n = 85)	p
Sex, female/male	1/31	20/65	0.01^*
Age, < 60/ ≥ 60	18/14	31/54	0.061
Operation mode, MWA + TACE/RFA + TACE	19/13	60/25	0.248
Hepatectomy before treatment, No/Yes	22/1	70/15	0.11
HBV, No/Yes	3/29	12/73	0.709
HCV, No/Yes	30/2	83/2	0.643
Cirrhosis, No/Yes	14/18	23/62	0.084
ALB, < 35/ ≥ 35	2/3	11/74	0.486
ALT, ≤ 40/ > 40	15/17	76/9	< 0.001^*
AST, ≤ 35/ > 35	21/11	56/29	0.979
AFP, < 200/ ≥ 200	29/3	58/27	0.013^*
Number, < 3/ ≥ 3	26/6	60/25	0.244
Tumor maximum diameter, < 30/ ≥ 30	23/9	51/34	0.235
Tumor maximum diameter, < 50/ ≥ 50	32/0	74/11	0.075
BCLC, A/B	27/5	59/26	0.102
Child–Pugh grade, A/B	32/0	81/4	0.498

RFA radiofrequency ablation, TACE transarterial chemoembolization, MWA microwave ablation, HBV hepatitis B virus, HCV hepatitis C virus, ALB albumin, AFP alpha fetoprotein, AST aspartate transaminase, ALT alanine transaminase, BCLC Barcelona Clinic Liver Cancer
^*Data are statistically significant results

ISSN: 1471-230X